GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnamed Holdings Corp (XCNQ:DMED) » Definitions » EBITDA Margin %

Diagnamed Holdings (XCNQ:DMED) EBITDA Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Diagnamed Holdings EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Diagnamed Holdings's EBITDA for the three months ended in Jun. 2024 was C$-0.17 Mil. Diagnamed Holdings's Revenue for the three months ended in Jun. 2024 was C$0.00 Mil. Therefore, Diagnamed Holdings's EBITDA margin for the quarter that ended in Jun. 2024 was 0.00%.


Diagnamed Holdings EBITDA Margin % Historical Data

The historical data trend for Diagnamed Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagnamed Holdings EBITDA Margin % Chart

Diagnamed Holdings Annual Data
Trend Sep21 Sep22 Sep23
EBITDA Margin %
- - -

Diagnamed Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Diagnamed Holdings's EBITDA Margin %

For the Health Information Services subindustry, Diagnamed Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diagnamed Holdings's EBITDA Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnamed Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Diagnamed Holdings's EBITDA Margin % falls into.



Diagnamed Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Diagnamed Holdings's EBITDA Margin % for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=-1.253/0
= %

Diagnamed Holdings's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-0.169/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diagnamed Holdings  (XCNQ:DMED) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Diagnamed Holdings EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Diagnamed Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Diagnamed Holdings Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.
Executives
Fabio Chianelli Director, Senior Officer

Diagnamed Holdings Headlines

No Headlines